8-K: Cytek Biosciences Q3 2025: Revenue Up 2%, Profitability Declines

Cytek Biosciences reported a 2% increase in total revenue to $52.3 million for Q3 2025, alongside significant declines in gross profit, net income, and Adjusted EBITDA.

Summary

• Total revenue for the third quarter of 2025 reached $52.3 million, marking a 2% increase compared to $51.5 million in Q3 2024.
• The company expanded its total installed base to 3,456 Cytek instruments, adding 161 units during Q3 2025.
• GAAP gross profit decreased by 5% to $27.6 million, with GAAP gross profit margin falling to 53% from 56% in Q3 2024.
• Net loss for Q3 2025 was $5.5 million, a significant decline from a net income of $0.9 million in Q3 2024.
• Adjusted EBITDA decreased to $2.5 million in Q3 2025 from $7.6 million in Q3 2024.
• General and administrative expenses surged by 47% to $16.1 million, primarily due to litigation-related expenses and a $0.7 million write-off of deferred offering costs for an expired 2022 ATM equity financing facility.
• Cytek Biosciences reaffirmed its full year 2025 revenue guidance in the range of $196 million to $205 million, representing -2% to +2% growth over full year 2024.

Sentiment

Score: 4

Explanation: While revenue saw a modest increase and recurring revenue streams showed strong growth, the significant decline in profitability metrics (gross profit, net income, Adjusted EBITDA) and the substantial increase in G&A expenses due to litigation and a write-off indicate underlying operational challenges. The reaffirmed guidance suggests a flat to slightly positive outlook for the full year, which is not particularly strong given the Q3 performance.

Positives

• Total revenue increased by 2% year-over-year to $52.3 million in Q3 2025.
• The installed base of Cytek instruments grew by 161 units in Q3 2025, reaching a total of 3,456.
• Worldwide revenue from biotechnology, pharmaceutical, and clinical research organization (CRO) customers increased by 14% year-over-year.
• Total recurring revenue, comprising service and reagent revenues, grew by 19% compared to Q3 2024.
• Double-digit total revenue growth was achieved year-over-year in all regions except EMEA.
• Expanded European headquarters in Amsterdam, increasing footprint by over 40% and adding a customer service and training center.

Negatives

• GAAP gross profit decreased by 5% to $27.6 million in Q3 2025 compared to $29.0 million in Q3 2024.
• GAAP gross profit margin declined to 53% in Q3 2025 from 56% in Q3 2024.
• Adjusted gross profit margin decreased to 55% from 60% in Q3 2024.
• Operating expenses increased by 10% to $36.7 million in Q3 2025.
• Loss from operations widened to $9.2 million in Q3 2025 from $4.2 million in Q3 2024.
• Net loss was $5.5 million in Q3 2025, a significant reversal from a net income of $0.9 million in Q3 2024.
• Adjusted EBITDA decreased substantially to $2.5 million in Q3 2025 from $7.6 million in Q3 2024.
• General and administrative expenses increased by 47% due to litigation-related expenses and a $0.7 million write-off of deferred offering costs.
• Continued softness in revenue was observed in the EMEA region.

Risks

• Global geopolitical, economic, and market conditions could impact business.
• Ability to manage the impacts of recent and future export controls and licensing requirements, tariffs, and NIH funding policies on the business.
• Ability to evaluate prospects for future viability and predict future performance.
• Ability to accurately forecast customer demand and adoption of products.
• Ability to recognize the anticipated benefits of collaborations.
• Dependence on certain sole and single source suppliers.
• Competition in the cell analysis solutions market.
• Market acceptance of current and potential products.
• Ability to manage the growth and complexity of the organization, maintain relationships with customers and suppliers, and hire and retain key employees.
• Ability to manufacture products in high-quality commercial quantities successfully and consistently to meet demand.
• Ability to increase penetration in existing markets and expand into adjacent markets.
• Ability to secure additional distributors or maintain good relationships with existing distributors.
• Ability to successfully develop and introduce new products.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to continue to stay in compliance with material contractual obligations, applicable laws, and regulations.
• Foreign currency exchange impacts could affect financial performance.

Future Outlook

Cytek Biosciences reaffirms its full year 2025 revenue guidance to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024, assuming no change from current currency exchange rates. Management remains focused on expanding the global installed base, growing recurring revenue streams, and achieving profitability and cash generation, believing the company is well-positioned to deliver long-term value.

Management Comments

• "Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position."
• "As we look ahead, our team remains sharply focused on expanding our global installed base, growing our recurring revenue streams and on profitability and cash generation."
• "While we remain mindful of market conditions, we believe Cytek is well-positioned to deliver long-term value for all of our stakeholders through the strong and disciplined execution of our strategic priorities."

Industry Context

The company operates in the cell analysis solutions market, a segment of the broader life sciences and biotechnology industry. The growth in revenue from biotechnology, pharmaceutical, and CRO customers suggests continued demand within these research-intensive sectors. The expansion of the European headquarters indicates a commitment to global market presence, despite reported softness in the EMEA region, which could reflect localized economic or competitive pressures.

Comparison to Industry Standards

• NA

Legal Proceedings

• General and administrative expenses increased due to litigation-related expenses.

Stakeholder Impact

• Shareholders: Impacted by the net loss and reduced profitability, potentially affecting stock performance. The company aims to deliver long-term value.
• Customers: Benefit from an expanded installed base of instruments and an enlarged European headquarters with a new customer service and training center.
• Employees: Management's focus on growth and strategic priorities could imply stability, but increased G&A expenses and profitability concerns might raise questions about future resource allocation.

Next Steps

• Host a conference call on November 5, 2025, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss Q3 2025 financial results.
• File the Quarterly Report on Form 10-Q for the period ended September 30, 2025, with the SEC on or about November 5, 2025.

Key Dates

Recommendation

The company shows mixed results with modest revenue growth driven by recurring revenue and customer expansion, but significant declines in profitability metrics (gross profit, net income, Adjusted EBITDA) and increased operating expenses due to litigation. While the installed base is growing and the company is expanding its European footprint, the financial deterioration in Q3 2025, coupled with a flat to slightly positive full-year guidance, suggests a cautious 'hold' stance. Investors should monitor future quarters for signs of improved profitability and expense management before considering a stronger position.

Keywords

Cell Analysis, Flow Cytometry, Biotechnology, Life Sciences, Financial Results, Q3 2025, Cytek Biosciences, CTKB, FSP Technology, Research Use Only